Biomind Labs Inc. (BMNDF)

OTCMKTS · Delayed Price · Currency is USD
0.1140
0.00 (0.00%)
Mar 4, 2026, 9:30 AM EST
Market Cap8.84M
Revenue (ttm)n/a
Net Income-113.80K
EPS-0.00
Shares Out77.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume2,536
Open0.1140
Previous Close0.1140
Day's Range0.1140 - 0.1140
52-Week Range0.0158 - 0.7000
Beta-0.72
RSI44.81
Earnings DateMar 31, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol BMNDF
Full Company Profile

Financial Performance

Financial Statements